
Biosimilars: To Infinity and Beyond - On Demand
Recorded On: 11/14/2023
-
Register
- Prices available after logging in
As biosimilars continue to expand their footprint in healthcare, their role in home and alternate site settings is becoming increasingly significant. With a growing number of biosimilars available and interchangeable options emerging, this session explores what the future holds for these innovative therapies. This session will delve into key concepts such as transitioning from parent products to biosimilars, understanding interchangeability, and addressing practical considerations for their use in clinical practice. Learners will gain valuable insights into the legislative, regulatory, and operational factors shaping biosimilar adoption in these care settings. This session is designed for pharmacists, pharmacy technicians, and nurses.
Learning Objectives:
- Review the legislative impact for pharmacies as it relates to interchangeability of approved molecules in clinical practice.
- Review current requirements for FDA approval of biosimilars and interchangeability requirements for biosimilars.
- Describe potential processes to overcome barriers to biosimilar adoption (prescribing, financial, operational).

Jonathan Ogurchak, PharmD, CSP
Co-Founder & CEO
STACK
Jonathan Ogurchak is the Founder & CEO of STACK, a compliance management software designed to simplify the “outside of the dispense” complexities associated with running successful pharmacy organizations. He is also Managing Partner of Rhythm Group, consulting and technology solutions organization, and is a Certified Consultant with Accreditation Commission for Health Care (ACHC). Jonathan has designed programs and services for both Accredo and PANTHERx Specialty Pharmacy focusing on implementing innovative uses for technology, including high-touch pharmacist-driven programs focused on dosing efficiency, clinical monitoring of patient outcomes, and integrated patient engagement. Jonathan is on faculty for the Master of Pharmacy Business Administration (MPBA) program through the University of Pittsburgh, leading the Specialty Pharmacy Management curriculum. He currently serves on the editorial board for Specialty Pharmacy Times, holds CSP Certification through the Specialty Pharmacy Certification Board, and serves as an Educational Consultant for the National Association of Specialty Pharmacy (NASP).
NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy.
Jonathan Ogurchak has no relevant financial relationships with ineligible companies to disclose.
Key:




